Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

HIV vaccine in worldwide trial

08.10.2003


Vanderbilt is one of nine US sites



Vanderbilt University Medical Center is participating in worldwide tests of a potential vaccine that can stimulate important immune responses against the virus that causes AIDS.

This is the first candidate vaccine against the human immunodeficiency virus (HIV) to be studied simultaneously in so many locations, from Brazil to Thailand, according to Merck & Co. Inc., which developed the vaccine.


Vanderbilt currently is testing six potential AIDS vaccines, but the Merck product has gone farther than any other in generating cellular immune responses in preliminary human tests, says Dr. Paul Spearman, co-principal investigator of the Vanderbilt HIV Vaccine Program, one of nine U.S. sites to participate in the study.

Cellular immune responses refer to the production of a type of white blood cell, known as a cytotoxic or "killer" T-cell, which can clear its virus-infected neighbors from the bloodstream. Scientists believe that by speeding up production of these cells, a vaccine may be able to prevent the virus from spreading in the body.

"It may not prevent infection, but it might stimulate a response that would prevent the disease that results from the infection," Spearman says.

The Vanderbilt program is part of the federally funded HIV Vaccine Trials Network, an international coalition of scientists and institutions dedicated to accelerating the search for an HIV vaccine. This is the first collaboration between Merck and the network. The phase I trial is designed to test – at varying doses -- the vaccine’s safety and ability to stimulate immune responses in healthy, uninfected volunteers between the ages of 18 and 50. Of the 435 volunteers who will participate in the study worldwide, about a dozen will be tested at Vanderbilt.

Volunteers will be randomly selected to receive three injections of the either the vaccine or an inactive "placebo." The study involves 24 clinic visits and 22 blood tests over the course of 18 months.

A goal of the study is to see whether a single vaccine can generate significant immune responses in diverse populations throughout the world. If the trial is successful, more extensive testing will be conducted, ultimately leading to studies in people at risk of being infected with HIV.

The research is moving "fairly quickly," Spearman says. "We’re really hopeful."

The vaccine consists of a synthetically produced HIV gene – which cannot cause HIV infection. The gene is carried by an adenovirus, which normally can cause symptoms of the common cold, but which has been genetically altered so that is harmless. Side effects of the vaccine in preliminary human studies have been mild. They include soreness at the injection site and, at higher doses than will be used in this study, flu-like symptoms in some people.

Clinton Colmenares | EurekAlert!
Further information:
http://www.hivvaccineresearch.com
http://www.mc.vanderbilt.edu/reporter/

More articles from Health and Medicine:

nachricht Chronic stress induces fatal organ dysfunctions via a new neural circuit
21.08.2017 | Hokkaido University

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Nagoya physicists resolve long-standing mystery of structure-less transition

21.08.2017 | Materials Sciences

Chronic stress induces fatal organ dysfunctions via a new neural circuit

21.08.2017 | Health and Medicine

Scientists from the MSU studied new liquid-crystalline photochrom

21.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>